Literature DB >> 11312656

Vesicular release of ebola virus matrix protein VP40.

J Timmins1, S Scianimanico, G Schoehn, W Weissenhorn.   

Abstract

We have analysed the expression and cellular localisation of the matrix protein VP40 from Ebola virus. Full-length VP40 and an N-terminal truncated construct missing the first 31 residues [VP40(31-326)] both locate to the plasma membrane of 293T cells when expressed transiently, while a C-terminal truncation of residues 213 to 326 [VP40(31-212)] shows only expression in the cytoplasm, when analysed by indirect immunofluorescence and plasma membrane preparations. In addition, we find that full-length VP40 [VP40(1-326)] and VP40(31-326) are both released into the cell culture supernatant and float up in sucrose gradients. The efficiency of their release, however, is dependent on the presence of the N-terminal 31 residues. VP40 that is released into the supernatant is resistant to trypsin digestion, a finding that is consistent with the formation of viruslike particles detected by electron microscopy. Together, these results provide strong evidence that Ebola virus VP40 is sufficient for virus assembly and budding from the plasma membrane. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11312656     DOI: 10.1006/viro.2001.0860

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  106 in total

1.  Role of ESCRT-I in retroviral budding.

Authors:  Juan Martin-Serrano; Trinity Zang; Paul D Bieniasz
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

2.  Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding.

Authors:  Ziying Han; Hani Boshra; J Oriol Sunyer; Susan H Zwiers; Jason Paragas; Ronald N Harty
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

3.  Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4.

Authors:  Jillian M Licata; Martha Simpson-Holley; Nathan T Wright; Ziying Han; Jason Paragas; Ronald N Harty
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

4.  The matrix protein of Marburg virus is transported to the plasma membrane along cellular membranes: exploiting the retrograde late endosomal pathway.

Authors:  Larissa Kolesnikova; Sandra Bamberg; Beate Berghöfer; Stephan Becker
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

5.  The importance of the NP: VP35 ratio in Ebola virus nucleocapsid formation.

Authors:  Takeshi Noda; Larissa Kolesnikova; Stephan Becker; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

6.  Unconventional secretion of Ebola virus matrix protein VP40.

Authors:  Olivier Reynard; St Patrick Reid; Audrey Page; Mathieu Mateo; Nathalie Alazard-Dany; Hervé Raoul; Christopher F Basler; Viktor E Volchkov
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

7.  Viral and host proteins that modulate filovirus budding.

Authors:  Yuliang Liu; Ronald N Harty
Journal:  Future Virol       Date:  2010-07-01       Impact factor: 1.831

8.  Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.

Authors:  Masahiro Kajihara; Andrea Marzi; Eri Nakayama; Takeshi Noda; Makoto Kuroda; Rashid Manzoor; Keita Matsuno; Heinz Feldmann; Reiko Yoshida; Yoshihiro Kawaoka; Ayato Takada
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

9.  Impact of Měnglà Virus Proteins on Human and Bat Innate Immune Pathways.

Authors:  Caroline G Williams; Joyce Sweeney Gibbons; Timothy R Keiffer; Priya Luthra; Megan R Edwards; Christopher F Basler
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

10.  Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction.

Authors:  R N Harty; M E Brown; J P McGettigan; G Wang; H R Jayakar; J M Huibregtse; M A Whitt; M J Schnell
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.